Apollon Wealth Management LLC Grows Stake in Eli Lilly and Company $LLY

Key Points

• Apollon Wealth Management LLC increased its stake in Eli Lilly and Company by 12.5% during the second quarter, now owning 38,388 shares valued at approximately $29.9 million.
• Insider activity included purchases by EVP Daniel Skovronsky, who bought 1,000 shares at $634.40 each, increasing his ownership by 0.73%.
• Recent analyst ratings show a generally positive outlook for Eli Lilly, with Guggenheim raising the price target from $875.00 to $948.00 and a consensus rating of "Moderate Buy."

Apollon Wealth Management LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 12.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,388 shares of the company's stock after purchasing an additional 4,271 shares during the period. Apollon Wealth Management LLC's holdings in Eli Lilly and Company were worth $29,924,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of LLY. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth $27,000. Citizens National Bank Trust Department increased its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the first quarter worth $40,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Corporate insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Guggenheim raised their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research report on Wednesday. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. Finally, Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $948.56.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $833.08 on Friday. The business's fifty day moving average price is $742.42 and its 200 day moving average price is $765.94. The stock has a market capitalization of $788.47 billion, a P/E ratio of 54.45, a PEG ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.